Background and Need for Legislation
The INCLUDE (INvestigation of Co-occurring conditions
across the Lifespan to Understand Down syndromE) Project was
established in June 2018 at the direction of Congress to
conduct research on critical health and quality-of-life needs
for individuals with Down syndrome. The project investigates
conditions that affect individuals with Down syndrome and the
general population, such as Alzheimer's disease and dementia,
autism, cataracts, celiac disease, congenital heart disease,
and diabetes.\1\ Individuals with Down syndrome have an
increased risk of various medical conditions, including, but
not limited to, congenital cardiac issues, autoimmune
conditions, and Alzheimer's disease.\2\ The life expectancy for
individuals with Down syndrome has increased from roughly 25
years old in 1983 to roughly 60 years old today.\3\
Approximately half of people with Down syndrome will develop
dementia due to Alzheimer's disease; by 40 years old, the
majority of people with Down syndrome are at a heightened risk
for developing Alzheimer's disease.\4\ Additionally, across
their lifespan, individuals with Down syndrome typically have
multiple co-occurring conditions.\5\ Further research would
help improve the quality of life for people with Down syndrome,
as well as other individuals who may be facing the same medical
issues.\6\
---------------------------------------------------------------------------
\1\INCLUDE Project | National Institutes of Health (NIH).
\2\National Down Syndrome Society, Facts About Down Syndrome
(2022), https://ndss.org/sites/default/files/2022-08/2022 Down Syndrome
Fact Sheet.pdf.
\3\Id.
\4\National Institute on Aging (NIA), Alzheimer's Disease in People
with Down Syndrome (Nov. 30, 2020), https://www.nia.nih.gov/health/
alzheimers-causes-and-risk-factors/alzheimers-disease-people-down-
syndrome.
\5\Santoro & Bulova., Common Health Conditions in Adults with Down
Syndrome (Oct. 2025), National Down Syndrome Society, https://
careds.org/wp-content/uploads/Common-Health-
Conditions_Reference-Article.pdf.
\6\NIA, supra note 3.
---------------------------------------------------------------------------
Committee Action
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 3491. The title of the hearing was
``Legislative Proposals to Support Patients and Caregivers.''
The Subcommittee received testimony from:
Dr. Andy Shih, PhD, Chief Science Officer,
Autism Speaks;
Mr. Corey Feist, JD, MBA, Co-Founder and
CEO, Dr. Lorna Breen Heroes' Foundation;
Dr. Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Dr. Gordon Tomaselli, MD, Former President,
American Heart Association; Marilyn and Stanley M. Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Ms. Michelle Whitten, President, CEO, and
Co-Founder, Global Down Syndrome Foundation;
Mr. Randy Strozyk, President, American
Ambulance Association; and,
Dr. Christina Annunziata, MD, PhD, Senior
Vice President of Extramural Discovery Science,
American Cancer Society.
On March 12, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 7406, as amended, to the full
Committee by a voice vote.
On March 20, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 7406, as
amended, favorably reported to the House by a record vote of 45
yeas and 0 nays.
On May 21, 2026, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 3491, without
amendment, favorably reported to the House by a record vote of
46 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to promote
the scientific understanding of Down syndrome and co-occurring
conditions.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 3491 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 3491:
On February 14, 2024, the Subcommittee on
Health held a legislative hearing on H.R. 7268. The
title of the hearing was ``Legislative Proposals to
Support Patients and Caregivers.'' The Subcommittee
received testimony from:
Dr. Andy Shih, PhD, Chief
Science Officer, Autism Speaks;
Mr. Corey Feist, JD, MBA, Co-
Founder and CEO, Dr. Lorna Breen Heroes'
Foundation;
Dr. Joanne Pike, DrPH, President
and CEO, Alzheimer's Association;
Dr. Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley M. Katz Dean, Emeritus and
Professor of Medicine, Albert Einstein College
of Medicine; Adjunct Professor of Medicine,
Johns Hopkins University School of Medicine;
Ms. Michelle Whitten, President,
CEO, and Co-Founder, Global Down Syndrome
Foundation;
Mr. Randy Strozyk, President,
American Ambulance Association; and,
Dr. Christina Annunziata, MD,
PhD, Senior Vice President of Extramural
Discovery Science, American Cancer Society.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 3491 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``DeOndra Dixon INCLUDE
Project Act of 2025.''
Section 2. DeOndra Dixon INCLUDE Project
Section 2 directs the Secretary of the Department of Health
and Human Services, acting through the Director of the National
Institutes of Health, to establish and oversee the
implementation of a research program focused on Down syndrome.
This section also specifies certain program components that
should be investigated and included within the research
program, as well as implements Congressional reporting
requirements.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (new matter is
printed in italics and existing law in which no change is
proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE IV--NATIONAL RESEARCH INSTITUTES
* * * * * * *
Part B--General Provisions Respecting National Research Institutes
* * * * * * *
SEC. 409K. DOWN SYNDROME RESEARCH.
(a) In General.--The Director of NIH shall carry out a
program of research, training, and investigation related to
Down syndrome to be known as the ``INvestigation of Co-
occurring conditions across the Lifespan to Understand Down
syndromE Project'' or the ``INCLUDE Project''.
(b) Program Elements.--The program under subsection (a) shall
include--
(1) high-risk, high-reward research on the effects of
trisomy 21 on human development and health;
(2) promoting research for participants with Down
syndrome across the lifespan, including cohort studies
to facilitate improved understanding of Down syndrome
and co-occurring conditions and development of new
interventions;
(3) expanding the number of clinical trials that are
inclusive of, or expressly for, participants with Down
syndrome, including novel biomedical and
pharmacological interventions and other therapies
designed to promote or enhance activities of daily
living;
(4) research on the biological mechanisms in
individuals with Down syndrome pertaining to
structural, functional, and behavioral anomalies and
dysfunction as well as stunted growth;
(5) supporting research to improve diagnosis and
treatment of conditions co-occurring with Down
syndrome, including the identification of biomarkers
related to risk factors, diagnosis, and clinical
research and therapeutics;
(6) research on the causes of increased prevalence,
and concurrent treatment, of co-occurring conditions,
such as Alzheimer's disease and related dementias and
autoimmunity, in individuals with Down syndrome; and
(7) research, training, and investigation on
improving the quality of life of individuals with Down
syndrome and their families.
(c) Coordination; Prioritizing Nonduplicative Research.--The
Director of NIH shall ensure that--
(1) the programs and activities of the institutes and
centers of the National Institutes of Health relating
to Down syndrome and co-occurring conditions are
coordinated, including through the Office of the
Director of NIH and priority-setting reviews conducted
pursuant to section 402(b)(3); and
(2) such institutes and centers, prioritize, as
appropriate, Down syndrome research that does not
duplicate existing research activities of the National
Institutes of Health.
(d) Consultation With Stakeholders.--In carrying out
activities under this section, the Director of NIH shall, as
appropriate and to the maximum extent feasible, consult with
relevant stakeholders, including patient advocates, to ensure
that such activities take into consideration the needs of
individuals with Down syndrome.
(e) Biennial Reports to Congress.--
(1) In general.--The Director of NIH shall submit, on
a biennial basis, to the Committee on Energy and
Commerce and the Subcommittee on Labor, Health and
Human Services, Education, and Related Agencies of the
Committee on Appropriations of the House of
Representatives and the Committee on Health, Education,
Labor, and Pensions and the Subcommittee on Labor,
Health and Human Services, Education, and Related
Agencies of the Committee on Appropriations of the
Senate, a report that catalogs the research conducted
or supported under this section.
(2) Contents.--Each report under paragraph (1) shall
include--
(A) identification of the institute or center
involved;
(B) a statement of whether the research is or
was being carried out directly by such
institute or center or by multiple institutes
and centers; and
(C) identification of any resulting real-
world evidence that is or may be used for
clinical research and medical care for patients
with Down syndrome.
* * * * * * *
[all]